Results 121 to 130 of about 10,523 (190)

PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Wei T, Li Z, Lin C, Yang Y, Tie C, Cai X, Lv F, Yang W, Ji L.   +8 more
europepmc   +1 more source

PCSK9 inhibitors are go [PDF]

Nature Reviews Drug Discovery, 2015
openaire   +1 more source

Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. [PDF]

Front Neurol
Liu J, Han C, Ji X, Cao H, Chen S, Tan C, Hao X, Joyama Y, Zou W, Li Y, Liu J.   +10 more
europepmc   +1 more source

Dual-targeted albumin nanoparticles for the Co-delivery of low-dose paclitaxel and PCSK9 inhibitor in melanoma treatment. [PDF]

Mater Today Bio
Chen L, Hu M, Yan HM, Ding XQ, Yang QX, Wang L, Pan H.   +6 more
europepmc   +1 more source

PCSK9 inhibitors: Going forward and beyond [PDF]

European Journal of Preventive Cardiology, 2020
openaire   +2 more sources

Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis. [PDF]

J Atheroscler Thromb
Shimizu Y, Yokouchi-Konishi T, Aoki-Kamiya C, Temukai M, Hizuka K, Sawada M, Kakigano A, Iwanaga N, Kanagawa T, Murai K, Makino H, Yoshimatsu J.   +11 more
europepmc   +1 more source

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8⁺ infiltration in glioma. [PDF]

Sci Rep
Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M.   +27 more
europepmc   +1 more source

Oligogenic Familial Hypercholesterolemia Treated by Combination Therapy of Statin, Ezetimibe, PCSK9 Inhibitor, and Lomitapide. [PDF]

Intern Med
Kojima N, Tada H, Takamura M.
europepmc   +1 more source

Therapeutic Persistence in the Management of Familial Hypercholesterolemia: A Case of Acquired PCSK9 Inhibitor Nonresponse. [PDF]

JACC Case Rep
Lin KH, Stone NJ.
europepmc   +1 more source

Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis. [PDF]

Eur Heart J Cardiovasc Pharmacother
Goto S, Goto S.
europepmc   +1 more source